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http://www.biomedcentral.com/1471-230X/13/45RESEARCH ARTICLE Open AccessA randomised controlled trial of a probiotic
‘functional food’ in the management of irritable
bowel syndrome
Lesley M Roberts1, Deborah McCahon1, Roger Holder1, Sue Wilson1 and FD Richard Hobbs2*Abstract
Background: Irritable Bowel Syndrome (IBS) is a common condition characterised by pain, distension and altered
bowel habit. Evidence suggests functional foods containing probiotics improve gastrointestinal transit, however,
data are limited by short follow-up periods and evaluation in selected populations.
Methods: A multi-centre, randomized, double blind, controlled trial to evaluate the effect of a probiotic vs non-
probiotic dairy product on symptoms in IBS with a constipation element (IBS – Constipation or IBS – Mixed profile).
Set in 13 general practices within central England. Individuals meeting the ROME III criteria for IBS, aged 18–65
completed a pre-study diary. Eligible individuals were randomized to consume dairy ‘yoghurt’ products which
either did or did not contain active probiotics twice daily and to complete a daily diary. Primary outcome was
subjective global assessment of symptom relief at week 4. Other outcomes comprised, IBS symptom scores, pain,
bloating and flatulence levels, stool frequency, stool consistency, ease of bowel movement and quality of life.
Results: 179 were randomized (91 active, 88 placebo). 76 (43 active, 33 placebo) completed the study. No significant
between group differences existed at 4 weeks (57% active vs 53% placebo, reported adequate relief (p = 0.71)).
By week 8, 46% active vs 68% placebo reported adequate relief (p = 0.03). This was sustained at week 12.
Conclusions: Significant improvements were reported for most outcomes in all trial participants but improvement did
not differ by group. This trial does not provide evidence for effectiveness of a probiotic in IBS, in variance with a body
of published literature and review conclusions. Differential drop out may however cloud interpretation of data.
UK Trial registration: ISRCTN78863629
Keywords: Probiotic, Functional food, IBS, RCTBackground
Functional foods are defined as foods which purport to
improve health or wellbeing. In 2007 a BMJ editorial called
for the closer evaluation of functional foods and recent
European Union regulation and directives have formalised
the need for such foodstuffs to support claims with robust
evidence [1]. Their use by the public has increased consid-
erably, especially in chronic symptomatic disorders with
limited treatment options. For example, for the large num-
bers of individuals suffering symptoms of irritable bowel
syndrome (IBS) where conventional treatment is often* Correspondence: richard.hobbs@phc.ox.ac.uk
2Department of Primary Care Health Sciences, Oxford University, 2nd Floor,
23-38 Hythe Bridge Street, Oxford OX1 2ET, UK
Full list of author information is available at the end of the article
© 2013 Roberts et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the orpoorly efficacious, the potential for alternative evidence
based therapies is considerable.
IBS, a functional bowel disorder, is a common problem
affecting a substantial proportion of the population, with
point prevalence estimates ranging from 10-30% [2-10].
It is associated with significantly reduced quality of life
[8,11,12] and it is known that many patients seek alter-
native strategies for symptom relief [13]. One of the sim-
plest and therefore potentially most attractive options to
patients is the inclusion of functional foods in the diet,
with increasing markets for ‘health drinks’ in the UK
[14] and elsewhere.
Among functional foods, probiotics have gained high
interest in recent years since gut microbiota may be in-
volved in gastro-intestinal (GI) functions and alterationsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cent systematic reviews [17-19] of the literature have
evaluated the impact of probiotics on IBS. These reviews
have highlighted the considerable heterogeneity in study
findings and also in outcomes, probiotic combinations
and study design. Therefore, despite the number of stud-
ies, the evidence base remains poor with data coming
largely from small or uncontrolled trials. Overall, within
the published literature and systematic reviews [19-22]
there is a suggestion that probiotics confer benefit al-
though limitations of available evidence and possibility of
publication bias are acknowledged. Larger well-designed
studies of probiotics in IBS are therefore required.
A well investigated fermented milk probiotic product,
containing a specific Bifidobacterium strain (Bifidobac-
terium lactis CNCM I-2494 (previously DN-173 010))
with lactic acid bacteria (Lactobacillus delbrueckii subsp.
bulgaricus and Streptococcus thermophilus), has shown
beneficial effects on gut functions in several small ran-
domised controlled studies [23-26]. The consumption of
this probiotic dairy product (PDP) was associated with
shortening of colonic transit time in patients with IBS
with predominant constipation (IBSC) together with im-
provement of abdominal distension and other GI symp-
toms [24] and modest reduction of GI discomfort in
primary care IBS-C patients [25].
This study aimed to compare improvement in subjec-
tive assessment of symptom relief, individual symptoms
and quality of life over a 12 week period in individuals
consuming this commercially available product (Danone,
France) and those consuming an inactive identical prod-
uct. The study focussed on IBS which included constipa-
tion as a feature (either constipation predominant or
mixed profile), which accounts for approximately 75% of
the IBS population, based on preliminary data on the
value of probiotics in this sub group [24].
Methods
Design overview
A randomized placebo controlled trial to compare symp-
tom and quality of life in patients with IBS taking a pro-
biotic or non- probiotic fermented dairy product was
conducted in primary care practices.
Setting and participants
13 general practices in the Midlands Research Practices
Consortium (MidReC) situated within the West Midlands,
UK. Patients were identified through searches of elec-
tronic patient records for symptomatic individuals with a
diagnosis of IBS > 6 months or having received two or
more prescriptions in the previous 24 months for anti-
spasmodics, bulking agents or laxatives. A confirmatory
screening questionnaire based on ROME III criteria [27]
was sent to all patients. Lower than anticipated yield, ledto administration of the screening questionnaire to all
patients aged 18–65 in five of the thirteen practices. No
other alterations were made to the study protocol during
trial conduct. General practitioners applied discretion to
prevent contact with patients considered inappropriate
for contact or inclusion, for example individuals known to
be in a terminal stage of illness or experiencing acute and
severe mental illness.
Study eligibility was assessed from the information
provided on the screening questionnaire plus telephone
follow-up to verify responses. Individuals were consid-
ered eligible for inclusion if they were aged 18–65, met
ROME III [27] criteria for a diagnosis of IBS with symp-
toms being present for > 6 months and reported a con-
stipation element to their symptom profile (either
constipation predominant or a mixed symptom profile).
Eligible patients were mailed a symptom diary for com-
pletion over the two weeks prior to their randomization
appointment. At the baseline recruitment clinic research
nurses confirmed eligibility and applied further study ex-
clusions: individuals reporting passing more than 3 soft
stools per day in the absence of laxative mediation during
the pre-study phase; individuals without problematic
symptoms judged by an IBS Symptom Severity Score
(IBS-SSS) [28] of <75; individuals with known organic dis-
ease or reporting clinical signs of alarm; individuals who
were pregnant, breast-feeding or lactose intolerant; indi-
viduals with a BMI >35 or <18, as this was deemed sug-
gestive of abnormal diet or function; and those with a
recent change of IBS medication (in the preceding month)
to reduce likelihood of co-intervention bias.Randomization and interventions
Blocked randomization lists (1:1 allocation) were pro-
duced by the lead statistician (RH) for each general prac-
tice site and held centrally. Because of the short shelf-life
of dairy products randomised allocation lists were sent to
the sponsors for product production prior to randomisa-
tion clinics so that two weeks supply of the relevant allo-
cated product was available at the point of randomization.
All volunteers gave written informed consent before inclu-
sion in the study.
The test product was a commercially available fer-
mented product containing Bifidobacterium lactis (strain
number I-2494 in French National Collection of Cultures
of Micro-organisms (CNCM, Paris, France; Danone col-
lection number DN-173 010) together with the two clas-
sical yoghurt starters, S. thermophilus (CNCM strain
number I-1630) and L. bulgaricus (CNCM strain numbers
I-1632 and I-1519). The test product contains 1.25×1010
colony forming unit (cfu) of Bifidobacterium lactis CNCM
I-2494 per cup and 1.2×109 cfu/cup of S. thermophilus
and L. bulgaricus.
579 contacts via 
telephone
269 excluded by
telephone contact
310 invited to
attend
236 attend
appointements
74 did not attend 
appointment
Total invited 13498
2580 screening
questionnaires returned
575 no data returned
1198 no abdominal 
pain and discomfort
807 abdominal pain
and discomfort
49 new
medication
25 inflammatory
bowel disease
121 unwilling to
participate
2 other clinical
trial/ research
14 pregnant/
breastfeeding
41 Lactose 
intolerant
3 IBS trial
1 cancer of colon,
intestine, stomach
579 potentially
eligible
184 Randomised 52 Researcher
excluded (Table 1)
92
Active product
92
Control product
4 excluded:
1age >65, years
1 BMI >35,
2 >3 stool per day
1 excluded:
1 BMI >35
91 Control 
product88 Active
product
60 reached 
primary endpoint
49 reached primary 
endpoint
Figure 1 CONSORT diagram of recruitment, randomization & primary endpoint numbers.
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Table 1 Exclusions made during randomisation clinics
Exclusion n = 52 (%)
Average baseline stools frequency >3 14 (27%)
Does not wish to participate 13 (25%)
BMI too high 9 (17%)
Pre study diary not fully completed 3 (6%)
Clinical signs of alarm 3 (6%)
BMI too low 1 (2%)
Anti-psychotic medication in last month 1 (2%)
Lactose intolerance or immunodeficiency 1 (2%)
Organic bowel disease 1 (2%)
2 week holiday during next 4 weeks 1 (2%)
Change of treatment for IBS in last 4 weeks 1 (2%)
History of laxative abuse 1 (2%)
Diet change in last 4 weeks 1 (2%)
IBS SSS less than 75 1 (2%)
General anaesthesia in last month 1 (2%)
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dairy product without probiotics and with similar lactose
content to the test product. Both the test and control
products were without flavour. Each pot contained 125 g.
Both products were specifically prepared for the study and
provided by Danone Research (Palaiseau, France). Nurses,
GPs, patients and the research team remained blind to
product allocation until all analyses had been completed.
In both groups consumption of the product twice daily
was instructed and all patients received a two week supply
of the allocated product in the first instance and instruc-
tions to collect repeat supplies fortnightly for 12 weeks.
Outcomes and follow-up
All patients returned completed daily diaries at follow-up
visits after 4, 8 and 12 weeks. The daily diary assessed
stool frequency and consistency (evaluated in accordance
with the Bristol stool scale) and bowel movement diffi-
culty (using a 5-point Likert scale which ranged from no
difficulty to extreme difficulty). Weekly entries assessed
subjective global assessment (SGA) [29,30] of symptom
relief (“Do you consider that in the past week you have
had adequate relief of your IBS symptoms?”) and individ-
ual IBS specific symptom assessment of bloating, pain and
flatulence (6 point Likert scale ranging from 0 (none) to 5
(very severe)).
Participants completed the Birmingham IBS Symptom
Score [31], the IBS SSS [27] and an IBS specific quality of
life (QoL) tool [32] at baseline and at weeks 4, 8 and 12.
The Birmingham Symptom Score [31] uses 11 questions
to assess pain, diarrhoea and constipation, scores range
from 0–100 for each dimension with higher scores indi-
cating greater well-being. The IBS –SSS [27] utilises fivequestions each generating a maximum score of 100 and a
total possible score of 500 with higher scores indicating a
greater symptom burden. The IBS specific QoL [32] tool
evaluates dimensions; dysphoria, interference with activity,
body image, health worry, food avoidance, social reaction,
sexual and relationship using 34 five point Likert state-
ments. Items are summed to create a total score with
higher scores indicating better QoL.
The primary outcome was pre-specified as SGA of symp-
tom relief at week 4 in line with the recent trial evidence
on which the study was powered [33] and after discussion
with the product manufacturer and sponsor. Comparison
of all other outcomes at weeks 4, 8 and 12 between groups
formed specified secondary outcome measures.
Statistical analysis
The sample size calculation was based on a previous study
[33] demonstrating a 20% between group difference (62%
active vs. 42% control) for SGA. Therefore, 107 patients
with IBS-C were required in each group to demonstrate a
20% difference between groups in proportions reporting
adequate IBS symptoms relief at week 4, with a signifi-
cance of 5% and 80% power. This was inflated to 240
patients to be divided in two groups of 120 to allow for
drop-outs. No stopping guidelines were in place due to
the short trial duration and assumed safety of a commer-
cially available product. Data analyses for all outcomes
were performed on an intention to treat basis (ITT) and
further analyses were undertaken to compare differences
in those not deviating from protocol (per protocol). Ana-
lyses were performed on available data for each parameter.
ANCOVA with primary care centre as a random effect,
baseline as a covariate and product as a fixed effect was
used to compare the intervention and control groups with
respect to all outcomes. Ordinal logistic regression with
centre and product as fixed effects was used to explore
change within each arm of the study. Analyses were
conducted using MINITAB version 14, S Plus version 8
and ML wiN version 2.1 statistical software.
Role of the funding source
The study was funded by Danone Ltd. Contracts including
a right to publication of all findings were approved and
signed by both parties prior to commencement of the re-
search. The funders contributed to discussion about study
design and selection of outcome measures. All subsequent
data review was blinded and the analysis was undertaken
independently of the funders. The paper was reviewed by
the sponsor and an expert nominated by them with some
requested changes included in the final version.
Results
In summary, of 13,498 individuals screened by question-
naire, 2580 responded. (Figure 1) Of these, 807 reported
Table 2 Baseline demographic data and symptom scores
of participants
Active
product
Control
product
n = 88 n = 91
Mean (SD) Mean (SD)
Age 44.66 (11.98) 43.71 (12.76)
BMI 26.75 (4.03) 25.85 (3.61)
Percentage
Male 15 15
Non-smoker 47 56
Light smoker (<10 per day) 8 6
Heavy smoker (>10 per day) 14 18
Former smoker 32 21
White ethnic group 91 86
Other ethnic group combined 9 14
Mental Health 10 1
Score
IBS-SSS (Max score 500 –
higher scores indicating greater
symptom burden
258.70 (86.51) 251.73 (76.13)
IBS symptoms (Birmingham Score)
(Max score 100 for all dimensions –
higher scores represent
greater well-being)
Constipation 47.31 (26.86) 49.08 (25.75)
Diarrhoea 84.58 (15.17) 85.62 (11.72)
Pain 62.50 (19.74) 60.95 (19.62)
Total 68.36 (12.00) 68.90 (11.07)
IBS specific symptoms (Scored 0–5
with greater scores indicating
greater symptom burden)
Pain 2.50 (1.08) 2.50 (1.08)
Bloating 3.13 (1.18) 3.16 (0.97)
Flatulence 3.18 (1.14) 2.88 (1.16)
Composite score 8.80 (2.65) 8.54 (2.50)
Stool frequency (Stools per day) 1.17 (0.93) 1.19 (0.96)
Stool consistency
(From Bristol Stool Form)
3.14 (1.64) 3.20 (1.60)
Bowel movement difficulty
(Scored 0–5 with higher scores
indicating greater difficulty)
1.38 (1.19) 1.18 (1.06)
IBS-QoL (Multi-item scale with
greater scores indicating better
quality of life)
Dysphoria 66.69 (27.72) 72.94 (23.49)
Activity interference 73.02 (23.06) 73.73 (21.12)
Body image 58.03 (26.07) 60.85 (23.60)
Health worry 56.77 (26.13) 64.65 (24.66)
Food avoidance 58.14 (28.53) 59.34 (30.55)
Social reaction 64.99 (26.08) 73.72 (24.34)
Table 2 Baseline demographic data and symptom scores
of participants (Continued)
Sexual 75.43 (31.85) 77.75 (26.72)
Relationship 75.43 (24.06) 80.86 (20.25)
Total score 66.45 (22.49) 70.78 (20.08)
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3 months and 579 were deemed potentially eligible. Tele-
phone screening excluded a further 269 individuals,
primarily because of a diarrhoea predominant form of IBS,
and 310 individuals were issued with a clinic appointment,
of which 236 attended. A further 52 were excluded for rea-
sons described in Table 1. One hundred and eighty four
individuals were randomized although 5 were subsequently
excluded when data quality checks revealed breached ex-
clusion criteria. Eighty eight individuals commenced
consumption of the active product and 91 of the control
product leading to an ITT population of 179 patients.
Groups were similar with respect to baseline IBS symp-
tom severity scores, demographics, medical history and
concomitant disease, with the exception of mental illness
with 9 individuals in the active group having a current
mental health diagnosis compared to 1 in the control
group (Table 2).
Primary outcome
Among the 179 randomized patients, 109 had available
data for SGA at week 4 (60 in active group; 49 in control
group). There were no between group differences in
SGA noted at week 4 with 56.7% of the active group and
53.1% of the control group reporting adequate symptom
relief (p = 0.71) (Table 3).
Large numbers of withdrawals accrued, with dropout
rates of 39% (70/179) at week 4, 48% (86/179) at week 8
and 55% (98/179) at week 12, despite efforts to follow-
up all participants. Withdrawal reasons were recorded
where provided by participants. Across both groups
drop-out was attributable to a range of factors including
dislike of product taste, changes in personal circum-
stances and reported adverse events such as nausea.
At week 8 greater benefit in terms of adequate symptom
relief was reported in the control group (68.3% reporting
relief versus 46.2%, p = 0.03) and this was sustained at
week 12 (75.8% versus 45.8%, p = 0.004) (Table 3).
Secondary outcomes
During the initial 4 weeks of the trial statistically signifi-
cant (at the p < 0.05 level) improvement from baseline was
reported in both groups for the majority of outcomes,
including improvements in symptoms scores, bloating,
flatulence, ease of bowel movement and quality of life
(Table 4). Although both groups reported improvement
there was no significant between group difference when
Table 3 Comparison of the proportions reporting
adequate symptom relief in intention to treat analyses
Subjective global
assessment (SGA)
Active
product
% (n)
Control
product
% (n)
Difference
between
the groups
p value
active vs
control
Week 4 56.7 (60) 53.1 (49) 3.61 0.707
Week 8 46.2 (52) 68.3 (41) −22.1 0.027
Week 12 45.8 (48) 75.8 (33) −29.9 0.004
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measures used, nor for any individual symptoms or
QoL outcomes (Table 4). The improvement from base-
line scores demonstrated at week 4 in both groups
remained significant for most outcomes at week 8.
The absence of a between group difference, however
remained constant with both groups demonstrating
similar improvements (Table 5).Table 4 Between and within group comparisons at week 4
Study parameter Active product
n Mean (week 4–
baseline) (SD)
p value* (change
from baseline)
IBS-SSS 41 −53.35 (81.98) <0.002
Birmingham IBS symptom scale
Constipation 59 9.44 (20.40) <0.001
Diarrhoea 59 3.88 (12.26) 0.007
Pain 60 7.89 (14.70) <0.001
Total score 60 6.10 (10.83) <0.001
IBS specific symptoms
Pain 60 −0.33 (1.19) 0.087
Bloating −0.66 (1.35) <0.001
Flatulence −0.51 (1.24) <0.001
Composite score −1.48 (3.03) 0.002
Stool frequency 417 0.07 (0.89) 0.202
Stool consistency 341 0.13 (1.20) 0.240
Bowel movement difficulty 341 −0.24 (0.97) 0.004
IBS Quality of life
Dysphoria 60 9.78 (16.89) <0.001
Activity interference 60 5.68 (10.97) 0.003
Body image 60 6.63 (16.28) <0.001
Health worry 60 7.92 (15.20) 0.001
Food avoidance 60 9.58 (16.01) 0.002
Social reaction 60 7.33 (14.23) 0.003
Sexual 59 4.24 (15.68) 0.171
Relationship 60 7.15 (15.54) <0.001
Total score 60 7.60 (10.88) <0.001
*ANCOVA with centre as a random effect, baseline as a covariate and product as a
**Ordinal logistic regression with centre and product fixed effects.
Stool frequency, consistency and bowel movement difficulty were recorded daily an
for these items.By week 12, however, change in scores differed signifi-
cantly between groups for the following outcomes; IBS
symptom severity score, IBS symptoms of constipation
and associated total score as measured by the Birmingham
score, IBS specific symptoms of pain, bloating and asso-
ciated total score. For all statistically significant out-
comes those receiving the control product demonstrated
greater improvement than those receiving the active
product (Table 5).
Per protocol analyses undertaken at each of the time
points (4, 8 and 12 weeks) did not significantly alter the
findings reported in the ITT analyses.
Discussion
Summary of main findings
In this double-blind randomized controlled trial of a com-
mercially available probiotic fermented dairy product (yog-
hurt) containing bifidobacterium animalis DN-173010 inControl product Active versus control
n Mean (week 4–
baseline) (SD)
p value* (change
from baseline)
p value**
44 −31.11 (78.57) 0.010 0.233
49 15.10 (21.59) <0.001 0.131
2.22 (10.17) 0.106 0.616
11.22 (18.34) <0.001 0.367
8.28 (11.10) <0.001 0.251
49 −0.61 (1.36) 0.001 0.109
48 −0.68 (1.12) <0.001 0.432
49 −0.36 (1.07) 0.0017 0.955
49 −1.69 (2.99) <0.001 0.264
341 0.04 (0.85) 0.607 0.648
269 0.31 (1.30) 0.007 0.184
271 −0.28 (0.89) 0.011 0.450
50 7.53 (15.54) 0.002 0.875
50 5.07 (13.77) 0.008 0.769
50 8.13 (17.37) 0.004 0.134
50 5.75 (16.17) 0.009 0.958
50 4.42 (18.76) 0.078 0.121
50 4.17 (14.10) 0.029 0.769
48 4.17 (20.36) 0.125 0.853
50 1.92 (12.43) 0.217 0.139
50 5.69 (12.60) 0.004 0.979
fixed effect.
d therefore n represents the number of data items (days) included in analysis
Table 5 Between and within group comparisons at weeks 8 and 12
WEEK 8
Study parameter A = Active product C = Control product A vs C
n Mean (week 12–
baseline) (SD)
p value* (change
from baseline)
n Mean (week 12–
baseline) (SD)
p value* (change
from baseline)
p value**
IBS-SSS 50 −58.30 (84.96) <0.001 40 −58.33 (73.37) <0.001 0.589
Birmingham IBS symptom scale
Constipation 52 13.78 (24.47) <0.001 41 17.24 (22.61) <0.001 0.302
Diarrhoea 4.25 (13.78) 0.210 2.15 (7.71) 0.064 0.907
Pain 11.28 (18.88) <0.001 13.66 (16.80) <0.001 0.257
Total score 8.71 (13.09) <0.001 9.44 (9.75) <0.001 0.265
IBS specific symptoms
Pain 53 −0.58 (1.24) 0.012 41 −0.66 (1.43) 0.002 0.292
Bloating 52 −0.80 (1.44) 0.005 −0.85 (1.26) <0.001 0.408
Flatulence 53 −0.54 (1.28) 0.002 40 −0.50 (1.08) 0.004 0.864
Composite score 52 −1.95 (3.43) 0.003 −1.96 (3.17) <0.001 0.374
Stool frequency 346 0.07 (0.95) 0.303 276 0.10 (0.05) 0.141 0.828
Stool consistency 290 0.18 (1.17) 0.042 218 0.50 (1.23) 0.001 0.098
Bowel movement difficulty 291 −0.43 (1.01) <0.001 224 −0.40 (0.78) <0.001 0.623
IBS Quality of life
Dysphoria 53 14.66 (19.87) <0.001 41 9.29 (13.95) <0.001 0.508
Activity interference 8.20 (14.74) 0.001 6.05 (12.99) 0.001 0.924
Body image 11.95 (15.98) <0.001 8.54 (13.46) <0.001 0.735
Health worry 13.29 (17.81) <0.001 7.62 (15.19) 0.002 0.428
Food avoidance 10.06 (17.63) <0.001 5.49 (17.84) 0.039 0.372
Social reaction 10.85 (16.18) <0.001 6.71 (12.21) <0.001 0.462
Sexual 8.41 (18.31) 0.006 7.05 (16.92) 0.005 0.554
Relationship 7.23 (18.64) 0.015 7.01 (9.88) <0.001 0.635
Total score 10.95 (13.14) <0.001 7.52 (10.22) <0.001 0.483
WEEK 12
IBS-SSS 43 −61.02 (75.78) <0.001 33 −97.24 (90.17) <0.001 0.028
Birmingham IBS symptom scale
Constipation 48 6.65 (22.56) 0.039 35 17.52 (23.60) <0.001 0.011
Diarrhoea 3.27 (11.17) 0.048 2.43 (10.60) 0.133 0.889
Pain 10.28 (14.09) <0.001 15.24 (17.38) <0.001 <0.107
Total score 6.07 (9.62) <0.001 10.10 (10.78) <0.001 <0.022
IBS specific symptoms
Pain 48 −0.59 (1.24) 0.002 34 −1.04 (1.33) <0.001 0.016
Bloating 48 −0.58 (1.39) 0.005 −1.35 (1.21) <0.001 0.006
Flatulence 48 −0.64 (1.04) 0.001 −0.76 (1.23) <0.001 0.383
Composite score 48 −1.81 (3.03) <0.001 −3.16 (3.05) <0.001 0.011
Stool frequency 311 −0.07 (0.75) 0.186 224 0.07 (0.82) 0.464 0.211
Stool consistency 247 0.26 (1.22) 0.045 181 0.31 (0.99) 0.012 0.784
Bowel movement difficulty 246 −0.35 (0.99) <0.001 180 −0.36 (0.86) <0.001 0.329
IBS Quality of life
Dysphoria 48 13.61 (20.12) <0.001 34 10.83 (10.68) <0.001 0.933
Activity interference 8.47 (12.31) <0.001 34 7.09 (8.73) <0.001 0.806
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Table 5 Between and within group comparisons at weeks 8 and 12 (Continued)
Body image 11.33 (14.16) <0.001 34 8.27 (14.08) 0.005 0.857
Health worry 14.15 (21.01) <0.001 34 9.07 (13.19) <0.001 0.634
Food avoidance 8.16 (20.45) 0.008 34 8.58 (13.37) <0.001 0.687
Social reaction 9.64 (17.15) <0.001 34 9.38 (8.74) <0.001 0.660
Sexual 8.07 (21.34) 0.031 32 10.55 (16.53) <0.001 0.382
Relationship 7.03 (15.81) 0.002 34 5.51 (9.22) <0.001 0.751
Total score 10.43 (12.92) <0.001 34 8.83 (6.12) <0.001 0.810
*ANCOVA with centre as a random effect, baseline as a covariate and product as a fixed effect.
**Ordinal logistic regression with centre and product fixed effects.
Stool frequency, consistency and bowel movement difficulty were recorded daily and therefore n represents the number of data items (days) included in analysis
for these items.
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ent, both the inactive (control) and active product groups
demonstrated significant improvement across a range of
symptom and quality of life outcomes. Improvement was
maintained throughout the 12-week period of observation.
Reductions in symptoms were, however, reported at simi-
lar levels in both groups when assessed in weeks 4 and 8.
At week 12 there was the suggestion of a benefit of the
control product over the active formulation but this is
likely to be attributable to differential drop-outs between
groups.
The sustained and large improvement observed in
both groups suggests there may be benefit from regular
consumption of a dairy product but does not suggest
any additional benefit of the addition of a probiotic to
such products. If such a benefit is accrued the mechan-
ism through which this works is unclear and product ef-
fect, regularisation of eating habits and increased fluid
intake are all possible explanations. The fact that bene-
fits were also accrued by control participants supports
these potential mechanisms of effect. In the absence of a
non-intervention group this effect cannot be confirmed
but the substantial effect size is worthy of further con-
sideration and exploration of sub-groups in which
greatest benefit is accrued would be advisable. In this
study there was the suggestion that drop-out may be re-
lated to baseline symptom severity with those remaining
in the study having greater baseline symptom severity
scores than those withdrawing (IBS SSS 264.15 versus
238.09, p = 0.04). This could suggest greater benefit was
accrued by those with more severe symptoms encour-
aging continued participation or may reflect and greater
motivation to pursue therapy in this group.
Study strengths and limitations
This primary care based RCT is one of the largest trials
of probiotics in IBS to date and one of the only func-
tional food trials to be conducted outside small hospital
populations. The main study limitation was not reaching
the target recruitment of 240 patients between the twoarms, with only 179 recruited of whom 109 provided
data for the primary outcome. The failure to meet the
trial target recruitment was due to a contractually fixed
end date for the trial and the 109 participants providing
4 week data reduced study power to 47%. However, at
study close the trial showed futility of continuance given
the observed lack of treatment benefit. A post-hoc re-
estimate of sample size, based on observed difference
in the study primary outcome (proportions 0.57 versus
0.53), indicated 2477 patients would have been required
in each arm to demonstrate a statistically significant
treatment effect.
The observed imbalance in the randomization numbers
was due to the study requirement to randomize eligible
patients prior to the baseline visit (to enable product
manufacture) and there was differential clinic attendance
by chance. Since the study power was reduced through a
high level of drop-outs and differential drop-out, it there-
fore remains a possibility that an effect of the active prod-
uct was missed. The high drop-out rate highlights the
difficulty of conducting functional food trials but does call
into question the acceptability of such interventions to
patients over even short periods.
Comparison with existing literature
This study focused only on individuals who had a consti-
pation element to their IBS since earlier data suggested
this might be the population who might obtain most bene-
fit from consumption of a probiotic: prior trials [34-36]
have suggested that daily consumption of fermented milk
products containing Bifidobacterium animalis DN-173
010 improves transit and alleviates bloating in individuals
with low stool frequency. However the heterogeneous
nature of the cohort recruited (some with a constipation
predominant form of IBS and others with a mixed profile)
may further mask an effect which would be demonstrated
in a more homogeneous IBS constipation predominant
patient group. Despite screening to ensure all participants
were symptomatic at baseline and with a constipation fea-
ture to their IBS, the mean number of stools passed daily
Roberts et al. BMC Gastroenterology 2013, 13:45 Page 9 of 10
http://www.biomedcentral.com/1471-230X/13/45at baseline was greater than one and the mean stool
consistency was 3 on the Bristol Stool Form Scale which
equates to only a slightly drier than average stool suggesting
this cohort did not comprise those with more significant
forms of constipation. Recruitment of participants with a
more extreme manifestation of constipation may have more
closely replicated the small hospital populations in previous
trials where modest benefits of probiotics were observed.
However, given the dominance of small positive trials in the
literature, it is also possible that the literature in this area is
subject to publication bias. This highlights the importance
of establishing the efficacy of treatments across the wide
range of IBS phenotypes if they are to be made widely avail-
able. If functional foods are to be advocated for a common
disorder like IBS it is important to have clear indications as
to the symptoms most likely to accrue benefit. This study
importantly illustrates that data from the presumed more
persistent and extreme IBS phenotypes seen in hospitals
cannot routinely be extrapolated to the general population.
The interest in the use of functional foods is demon-
strated by the large numbers of reviews conducted in
recent years [20,21,37-41]. Despite this major body of re-
view evidence, the trial evidence upon which it is based
remains limited. This carefully conducted double blind
randomized 12 week study assessing a wider range of out-
comes in a general population of IBS with a constipation
element, did not reproduce these earlier hospital based
findings. Explanations for this may be attributable to dif-
ferences in participant groups, outcomes and follow-up.
However this study best reflects current practice for the
majority of patients with IBS who might consider probiotic
milk products to try to reduce symptoms.
Implication for future research or clinical practice
Clinicians advising patients with IBS managed in the
community featuring a constipation element may wish
to suggest the inclusion of a fermented dairy product,
given that significant improvements were reported for
most outcomes in all trial participants. The requirement
of such products to contain a probiotic is not supported
by this study.
Further research is required to consider the mechanism
via which improvement in symptoms may be effected in
trials of this nature through consideration of dietary habits
and fluid intake. Such work will ensure the most accurate
dietary advice can be provided to patients.
Conclusions
Significant improvements were reported for most out-
comes in all trial participants but improvement did not
differ by intervention or placebo group. This trial there-
fore does not provide evidence for effectiveness of a pro-
biotic in IBS, in variance with much published literature
and review conclusions.Ethical approval
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